Multiple Myeloma Clinical Trials in Uniondale, New York

11 studies are recruiting for multiple myeloma in Uniondale, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

   The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06976476 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

   The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of e…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MSK Nassau, Uniondale, New York

   Locations

   237 in total

   Run by

   Pfizer

   See if you can join NCT05020236 on ClinicalTrials.gov

3. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

   Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superio…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MSK Nassau, Uniondale, New York

   Locations

   139 in total

   Run by

   Pfizer

   See if you can join NCT05623020 on ClinicalTrials.gov

4. A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

   The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07105059 on ClinicalTrials.gov

5. A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

   The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab, lenalidomide, bortezomib, and dexamethasone) is a safe treatment for people with newly diagnosed multiple myeloma (MM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07099391 on ClinicalTrials.gov

6. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

   The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whethe…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   11 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06083922 on ClinicalTrials.gov

7. A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

   The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07454382 on ClinicalTrials.gov

8. A Dietary Study for People With Multiple Myeloma

   The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd)…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07226609 on ClinicalTrials.gov

9. A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

   The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area [BSA]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their stan…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06679829 on ClinicalTrials.gov

10. A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

    The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06066346 on ClinicalTrials.gov

11. A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

    The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermine…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06055894 on ClinicalTrials.gov